Rhumbline Advisers Has $2.26 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rhumbline Advisers boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 7.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 334,032 shares of the company’s stock after buying an additional 23,564 shares during the period. Rhumbline Advisers owned approximately 0.09% of Recursion Pharmaceuticals worth $2,258,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RXRX. Charles Schwab Investment Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after buying an additional 288,926 shares during the period. Accel Wealth Management acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth approximately $310,000. FMR LLC lifted its stake in Recursion Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after buying an additional 170,810 shares in the last quarter. Avanza Fonder AB acquired a new position in Recursion Pharmaceuticals in the 4th quarter worth $580,000. Finally, State Street Corp raised its position in Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after buying an additional 4,120,685 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the subject of several research reports. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday. Finally, KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $6.59 on Tuesday. Recursion Pharmaceuticals, Inc. has a one year low of $5.60 and a one year high of $12.93. The business’s 50 day simple moving average is $7.71 and its 200 day simple moving average is $7.09. The stock has a market capitalization of $2.57 billion, a PE ratio of -4.31 and a beta of 0.86. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.42) EPS. As a group, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.